184 related articles for article (PubMed ID: 26335012)
1. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
[TBL] [Abstract][Full Text] [Related]
2. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
[TBL] [Abstract][Full Text] [Related]
3. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
5. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice.
Matsuda Y; Yoshimura H; Ueda J; Naito Z; Korc M; Ishiwata T
Am J Pathol; 2014 Mar; 184(3):674-85. PubMed ID: 24412093
[TBL] [Abstract][Full Text] [Related]
6. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.
Song X; Chen H; Zhang C; Yu Y; Chen Z; Liang H; Van Buren G; McElhany AL; Fisher WE; Lonard DM; O'Malley BW; Wang J
Cancer Lett; 2019 Feb; 442():310-319. PubMed ID: 30423406
[TBL] [Abstract][Full Text] [Related]
7. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
8. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
9. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo.
Chen Y; Xie D; Yin Li W; Man Cheung C; Yao H; Chan CY; Chan CY; Xu FP; Liu YH; Sung JJ; Kung HF
Cancer Lett; 2010 Nov; 297(1):109-16. PubMed ID: 20684863
[TBL] [Abstract][Full Text] [Related]
10. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Tan J; Zhou X; Zhu H
Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
[TBL] [Abstract][Full Text] [Related]
12. Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer.
Matsuda Y; Ishiwata T; Yoshimura H; Yamahatsu K; Minamoto T; Arai T
Cancer Sci; 2017 Mar; 108(3):354-361. PubMed ID: 28002641
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
[TBL] [Abstract][Full Text] [Related]
14. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
15. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
17. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P
Oncotarget; 2017 Feb; 8(6):9216-9229. PubMed ID: 27999205
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
20. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]